References
- Sjöberg L, Karlsson B, Atti AR, Skoog I, Fratiglioni L, Wang HX. Prevalence of depression: Comparisons of different depression definitions in population-based samples of older adults. J Affect Disord. 2017;221:123–131. doi:10.1016/j.jad.2017.06.011.
- Malhi GS, Mann JJ. Depression. Lancet. 2018;392(10161):2299–2312. doi:10.1016/ S0140–6736(18)31948–2.
- Park LT, Zarate CA. Depression in the Primary Care Setting. N Engl J Med. 2019;380(6):559–568. doi:10.1056/NEJMcp1712493.
- Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature. 2008;455(7215):894–902. doi:10.1038/nature07455.
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Association; 2013. doi:10.1176/appi.books.9780890425596.
- McIntyre RS, Alsuwaidan M, Baune BT, et al. Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions. World Psychiatry. 2023;22(3):394–412. doi:10.1002/wps.21120.
- Döme P, Kunovszki P, Takács P, et al. Clinical characteristics of treatment-resistant depression in adults in Hungary: Real-world evidence from a 7-year-long retrospective data analysis. PLoS One. 2021;16(1):e0245510. doi:10.1371/journal.pone.0245510.
- World Health Organization. Depressive disorder (depression). 2023. Accessed November 20, 2024. https://www.who.int/news-room/fact-sheets/detail/depression.
- Zhdanava M, Pilon D, Ghelerter I, et al. The Prevalence and National Burden of Treatment-Resistant Depression and Major Depressive Disorder in the United States. J Clin Psychiatry. 2021;82(2). doi:10.4088/JCP.20m13699.
- Rotenstein LS, Ramos MA, Torre M, et al. Prevalence of Depression, Depressive Symptoms, and Suicidal Ideation Among Medical Students: A Systematic Review and Meta-Analysis. JAMA. 2016;316(21):2214–2236. doi:10.1001/jama.2016.17324.
- Centrala Narodowego Funduszu Zdrowia. NFZ o Zdrowiu. Depresja.; 2020.
- Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289(23):3095–3105. doi:10.1001/jama.289.23.3095.
- Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28–40. doi:10.1176/appi.ajp.163.1.28.
- Cepeda MS, Kern DM, Nicholson S. Treatment resistant depression in women with peripartum depression. BMC Pregnancy Childbirth. 2019;19(1):323. doi:10.1186/s12884–019–2462–9.
- Cooper C, Katona C, Lyketsos K, et al. A systematic review of treatments for refractory depression in older people. Am J Psychiatry. 2011;168(7):681–688. doi:10.1176/appi.ajp.2011.10081165.
- Azar AR, Chopra MP, Cho LY, Coakley E, Rudolph JL. Remission in major depression: results from a geriatric primary care population. Int J Geriatr Psychiatry. 2011;26(1):48–55. doi:10.1002/gps.2485.
- Kaplan MJ, Klinetob NA. Childhood emotional trauma and chronic posttraumatic stress disorder in adult outpatients with treatment-resistant depression. J Nerv Ment Dis. 2000;188(9):596–601. doi:10.1097/00005053–200009000–00006.
- Scott J, Eccleston D, Boys R. Can we predict the persistence of depression? Br J Psychiatry. 1992;161:633–637. doi:10.1192/bjp.161.5.633.
- McIntyre RS, Berk M, Brietzke E, et al. Bipolar disorders. Lancet. 2020;396(10265):1841–1856. doi:10.1016/S0140–6736(20)31544–0.
- Fava M, Rush AJ, Alpert JE, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry. 2008;165(3):342–351. doi:10.1176/appi. ajp.2007.06111868.
- Bartova L, Dold M, Kautzky A, et al. Results of the European Group for the Study of Resistant Depression (GSRD) – basis for further research and clinical practice. World J Biol Psychiatry. 2019;20(6):427–448. doi:10.1080/15622975.2019.1635270.
- McIntyre RS, Calabrese JR. Bipolar depression: the clinical characteristics and unmet needs of a complex disorder. Curr Med Res Opin. 2019;35(11):1993–2005. doi:10.1080/03007995.2019.16 36017.
- Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905–1917. doi:10.1176/ajp.2006.163.11.1905.
- Cuijpers P, van Straten A, Andersson G, van Oppen P. Psychotherapy for depression in adults: a meta--analysis of comparative outcome studies. J Consult Clin Psychol. 2008;76(6):909–922. doi:10.1037/ a0013075.
- Kennedy SH, Lam RW, McIntyre RS, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments. Can J Psychiatry. 2016;61(9):540–560. doi:10.1177/0706743716659417.
- Zimmerman M, Posternak M, Friedman M, et al. Which factors influence psychiatrists’ selection of antidepressants? Am J Psychiatry. 2004;161(7):1285–1289. doi:10.1176/appi.ajp.161.7.1285.
- Baldessarini RJ, Lau WK, Sim J, Sum MY, Sim K. Duration of initial antidepressant treatment and subsequent relapse of major depression. J Clin Psychopharmacol. 2015;35(1):75–76. doi:10.1097/ JCP.0000000000000263.
- Henssler J, Kurschus M, Franklin J, Bschor T, Baethge C. Trajectories of Acute Antidepressant Efficacy: How Long to Wait for Response? A Systematic Review and Meta-Analysis of Long-Term, Placebo-Controlled Acute Treatment Trials. J Clin Psychiatry. 2018;79(3). doi:10.4088/JCP.17r11470.
- Rosenblat JD, Simon GE, Sachs GS, et al. Treatment effectiveness and tolerability outcomes that are most important to individuals with bipolar and unipolar depression. J Affect Disord. 2019;243:116–120. doi:10.1016/j.jad.2018.09.027.
- Brignone M, Diamand F, Painchault C, Takyar S. Efficacy and tolerability of switching therapy to vortioxetine versus other antidepressants in patients with major depressive disorder. Curr Med Res Opin. 2016;32(2):351–366. doi:10.1185/03007995.2015.1128404.
- Scott F, Hampsey E, Gnanapragasam S, et al. Systematic review and meta-analysis of augmentation and combination treatments for early-stage treatment-resistant depression. J Psychopharmacol. 2023;37(3):268–278. doi:10.1177/02698811221104058.
- Zhou Y, Wang C, Lan X, et al. The effectiveness of repeated intravenous ketamine on subjective and objective psychosocial function in patients with treatment-resistant depression and suicidal ideation. J Affect Disord. 2022;304:78–84. doi:10.1016/j.jad.2022.02.032.
- Daly EJ, Singh JB, Fedgchin M, et al. Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2018;75(2):139–148. doi:10.1001/jamapsychiatry.2017.3739.
- Wajs E, Aluisio L, Holder R, et al. Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2). J Clin Psychiatry. 2020;81(3). doi:10.4088/JCP.19m12891.
- McIntyre RS, Rosenblat JD, Nemeroff CB, et al. Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. Am J Psychiatry. 2021;178(5):383–399. doi:10.1176/appi. ajp.2020.20081251.
- Schatzberg AF. A Word to the Wise About Intranasal Esketamine. Am J Psychiatry. 2019;176(6):422–424. doi:10.1176/appi.ajp.2019.19040423.
- Mohamed S, Johnson GR, Chen P, et al. Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial. JAMA. 2017;318(2):132–145. doi:10.1001/jama.2017.8036.
- Cha DS, McIntyre RS. Treatment-emergent adverse events associated with atypical antipsychotics. Expert Opin Pharmacother. 2012;13(11):1587–1598. doi:10.1517/14656566.2012.656590.
- Kumar A, Bunker MT, Aaronson ST, et al. Durability of symptomatic responses obtained with adjunctive vagus nerve stimulation in treatment-resistant depression. Neuropsychiatr Dis Treat. 2019;15:457–468. doi:10.2147/NDT.S196665.
- Zandi PP, Morreale M, Reti IM, et al. National Network of Depression Centers’ Recommendations on Harmonizing Clinical Documentation of Electroconvulsive Therapy. J ECT. 2022;38(3):159–164. doi:10.1097/YCT.0000000000000840.
- Grammer GG, Kuhle AR, Clark CC, Dretsch MN, Williams KA, Cole JT. Severity of Depression Predicts Remission Rates Using Transcranial Magnetic Stimulation. Front Psychiatry. 2015;6:114. doi:10.3389/fpsyt.2015.00114.
- Cole EJ, Phillips AL, Bentzley BS, et al. Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled Trial. Am J Psychiatry. 2022;179(2):132–141. doi:10.1176/appi. ajp.2021.20101429.
- Cladder-Micus MB, Speckens AEM, Vrijsen JN, T Donders AR, Becker ES, Spijker J. Mindfulness-based cognitive therapy for patients with chronic, treatment-resistant depression: A pragmatic randomized controlled trial. Depress Anxiety. 2018;35(10):914–924. doi:10.1002/da.22788.
- Dold M, Kasper S. Evidence-based pharmacotherapy of treatment-resistant unipolar depression. Int J Psychiatry Clin Pract. 2017;21(1):13–23. doi:10.1080/13651501.2016.1248852.
- Wilkinson ST, Rhee TG, Joormann J, et al. Cognitive Behavioral Therapy to Sustain the Antidepressant Effects of Ketamine in Treatment-Resistant Depression: A Randomized Clinical Trial. Psychother Psychosom. 2021;90(5):318–327. doi:10.1159/000517074.
- Rhee TG, Shim SR, Forester BP, et al. Efficacy and Safety of Ketamine vs Electroconvulsive Therapy Among Patients With Major Depressive Episode. JAMA Psychiatry. 2022;79(12):1162. doi:10.1001/ jamapsychiatry.2022.3352.